PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data

CONCLUSION: Combined IBC treatment achieved superior DCR and PFS compared with IC or BC in patients with PD-L1-negative metastatic lung adenocarcinoma, while did not increase the adverse events.PMID:38499838 | DOI:10.1007/s00432-024-05637-1

Source: Clinical Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Yihui Ge Yujing Zhan Jie He Juan Li Jian Wang Xiaojuan Wei Chunni Wang Aiqin Gao Yuping Sun Source Type: research